Bradykinin is a peptide studied in research settings, and it has no approved drug label from the FDA. Readers encountering this name in trial listings or lab contexts may want to understand what it is and how it is being investigated.
What bradykinin is
Bradykinin is a peptide compound with the molecular formula C50H73N15O11 and a molecular weight of approximately 1060.2 (PubChem CID 439201). No FDA-approved label exists for bradykinin, so there is no established drug class, mechanism statement, or approved indication to report. It remains a subject of research rather than an approved therapeutic.
Trial footprint
There are 150 registered clinical trials referencing bradykinin. Among the sampled studies, one Phase 3 trial, "Safety and Efficacy of Conestat Alfa for ACE-Induced Angioedema," has a status listed as unknown. A separate study, "Hereditary Angioedema Kininogen Assay," was terminated, and another trial examining dry needling and shoulder muscle blood flow, motions, and pain sensitivity has been completed. These studies reflect a range of research interests connected to bradykinin biology, including angioedema and musculoskeletal physiology, but they do not establish that bradykinin itself is a safe or effective treatment for any condition.